ArriVent BioPharma, Inc. Common Stock
Financials
Valuation Metrics
ArriVent BioPharma, Inc. Common Stock's Market Cap is $733M. At end of 2025 it was $774M. Ranked #2580 of 3,118 in US market (top 83%), #1091 of 1,474 on NASDAQ (top 74%), #198 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $733M | US#2,580/3,118 Sec#198/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-164M | US—/3,118 Sec—/265 |
| Total Assets | $395M | US#2,838/3,118 Sec#187/265 |
| Net Assets | $367M | US#2,418/3,118 Sec#143/265 |
| Employees | 77 | US#2,653/3,118 Sec#191/265 |
| Value | ||
| P/B | 2.00x | US#1,275/3,118 Sec#60/265 |
| FCF Yield | -20.18% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -44.63% | US#2,651/3,118 Sec#148/265 |
| ROA | -41.48% | US#2,945/3,118 Sec#193/265 |
| Financial Health | ||
| Debt Ratio | 7.60% | US#70/3,118 Sec#34/265 |
| Total Debt | $351000.00 | US#2,987/3,118 Sec#254/265 |
| FCF | $-148M | US#2,710/3,118 Sec#178/265 |
| Cash | $155M | US#1,934/3,118 Sec#132/265 |
| Current Ratio | 14.16x | US#174/3,118 Sec#52/265 |
| Performance | ||
| 1Y Return | -19.52% | US#2,392/3,118 Sec#189/265 |
| 1M Return | -50.91% | US#3,100/3,118 Sec#262/265 |
| From 52W High | -58.51% | US#2,814/3,118 Sec#220/265 |
| 1Y MDD | -57.21% | US#2,654/3,118 Sec#195/265 |
| Trading | ||
| Volume | 981,876 shares | US#1,511/3,118 Sec#141/265 |
| Trading Value | $15M | US#2,069/3,118 Sec#157/265 |
| Per Share | ||
| EPS | $-3.32 | US—/3,118 Sec—/265 |
| BPS | $7.44 | US#2,045/3,118 Sec#92/265 |
Company Info
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.